SEARCH RESULT

Total Matching Records found : 791

Holes in cancer drug price cap -GS Mudur

-The Telegraph Call to govt to adopt 'cost-based' control The 30 per cent cap on profit margins imposed by India’s drug pricing authority on 42 anti-cancer drugs will have a limited impact on patients’ expenses because many of these medicines’ prices remain “prohibitive”, a network of patients’ rights groups said on Saturday. The All India Drug Action Network (Aidan) said the National Pharmaceutical Pricing Authority’s cap on profit margins in effect “legitimises” the...

More »

NPPA caps trade margins of 42 cancer drugs at 30% -Sushmi Dey

-The Times of India NEW DELHI: The government has capped trade margins of 42 cancer drugs at 30% expanding the span of price control to curtail undue profiteering by chemists and drug stockists on various medicines which were so far outside price regulation. The move is expected to bring major relief to around 1.5 million cancer patients in India reeling under exponentially high treatment cost leading to heavy out-of-pocket expenditure. In a detailed...

More »

Govt forms Niti-led panel to monitor pricing of drugs -Rupali Mukherjee

-The Hindu Business Line MUMBAI: The government on Monday constituted a standing committee headed by Niti Aayog to oversee the drug pricing regime, a move which could clip the powers of drug pricing regulator, National Pharmaceutical Pricing Authority (NPPA). The Standing Committee on Affordable Medicines and Health Products will be headed by NITI Aayog member (health), and includes chief economic adviser, besides secretary department of health research, director general of health...

More »

Health ministry mulled compulsory licencing of rare disease drugs -Sushmi Dey

-The Times of India NEW DELHI: The health ministry was actively mulling compulsory licensing, apart from price capping, of “orphan drugs” (for rare diseases), when the department of pharmaceuticals abruptly issued an order exempting such medicines from price control, derailing plans to make these drugs affordable. The health ministry discussed price capping and invoking compulsory licence for these “exorbitantly” priced “orphan drugs” at a meeting on January 3, the day when DoP...

More »

'Many combination drugs not approved by regulator' -Afshan Yasmeen

-The Hindu Study raises safety, efficacy concerns; call for ban of irrational formulations Of the 110 anti-TB (tuberculosis) Fixed Dose Combinations (FDCs) available in India, only 32 (less than 30%) have been approved by the Central Drugs Standard Control Organisation (CDSCO), the country’s drug regulator. In the case of malaria FDCs, only eight out of 20 (40%), have been approved. These statistics, that give rise to safety and efficacy concerns, have been brought...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close